Figure 5

Dipyridamole does not amplify prednisolone effects on surrogate markers of osteoporosis. BL/6 mice were dosed twice daily with test agents for a total of 8 weeks to measure effects on markers of bone homeostasis. (a) Serum was collected at the end of the study and osteocalcin was measured by ELISA. (b) End of study mid-shaft femur bone density was measured by flurochrome labeling, sectioning, and peripheral quantitative computed tomography. Prednisolone alone (grey curve); prednisolone in combination with dipyridamole twice daily (black curve); dipyridamole alone and vehicle control are indicated with open triangle and open circle, respectively; sub-cutaneous dexamethasone (5 mg/kg once daily) positive control is indicated with a black square. *P < 0.05 versus the vehicle control. Dipyridamole was dosed at 37.5 mg/kg twice daily in this study (allometrically scaled from a rat total daily dose of 150 mg/kg). Error bars are ± standard deviation, and statistical comparison is by analysis of variance with Tukey.